Sanofi (SNY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SNY SEC filings page.
Sanofi (SNY) reported $54.8B in revenue for fiscal year 2025, up 19.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sanofi's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sanofi has an operating margin of 13.6%, meaning the company retains $14 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is down from 16.4% the prior year.
Sanofi's revenue surged 19.6% year-over-year to $54.8B, reflecting rapid business expansion. This strong growth earns a score of 63/100.
Sanofi carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 75/100, indicating a strong balance sheet with room for future borrowing.
Sanofi's current ratio of 1.09 is below the typical benchmark, resulting in a score of 24/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Not available for Sanofi, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Sanofi's ROE of 10.9% shows moderate profitability relative to equity, earning a score of 63/100. This is up from 7.2% the prior year.
Sanofi passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Sanofi generates $1.38 in operating cash flow ($12.6B OCF vs $9.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Sanofi earns $13.05 in operating income for every $1 of interest expense ($7.4B vs $570.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Sanofi generated $54.8B in revenue in fiscal year 2025. This represents an increase of 19.6% from the prior year.
Sanofi reported $9.2B in net income in fiscal year 2025. This represents an increase of 59.3% from the prior year.
Sanofi earned $7.48 per diluted share (EPS) in fiscal year 2025. This represents an increase of 63.0% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Sanofi held $9.0B in cash against $16.9B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Sanofi's gross margin was 72.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.9 percentage points from the prior year.
Sanofi's operating margin was 13.6% in fiscal year 2025, reflecting core business profitability. This is down 2.8 percentage points from the prior year.
Sanofi's net profit margin was 16.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.2 percentage points from the prior year.
Sanofi's ROE was 10.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.8 percentage points from the prior year.
Capital Allocation
Sanofi invested $9.2B in research and development in fiscal year 2025. This represents an increase of 20.3% from the prior year.
Sanofi spent $5.9B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1782.8% from the prior year.
Not reported for fiscal year 2025.
SNY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.8B+19.6% | $45.8B-0.4% | $46.0B+6.1% | $43.4B-2.1% | $44.3B-3.0% | $45.7B+8.2% | $42.2B+3.4% | $40.9B-6.1% | $43.5B+18.9% | $36.6B-3.3% | $37.9B |
| Cost of Revenue | $15.3B+12.0% | $13.7B-2.2% | $14.0B+9.9% | $12.7B-8.4% | $13.9B-6.7% | $14.9B+10.6% | $13.4B+2.7% | $13.1B-6.2% | $14.0B+23.6% | $11.3B-4.8% | $11.9B |
| Gross Profit | $39.5B+22.8% | $32.2B+0.3% | $32.1B+4.5% | $30.7B+0.7% | $30.5B-1.2% | $30.8B+7.1% | $28.8B+3.7% | $27.8B-6.1% | $29.6B+16.8% | $25.3B-2.6% | $26.0B |
| R&D Expenses | $9.2B+20.3% | $7.7B+6.3% | $7.2B+3.5% | $7.0B+8.0% | $6.4B-4.7% | $6.8B+0.1% | $6.8B+0.1% | $6.8B+2.6% | $6.6B+20.5% | $5.5B-1.1% | $5.5B |
| Operating Income | $7.4B-0.8% | $7.5B-2.5% | $7.7B-29.2% | $10.9B+18.2% | $9.2B-46.7% | $17.3B+403.9% | $3.4B-36.1% | $5.4B-23.2% | $7.0B+1.2% | $6.9B+12.8% | $6.1B |
| Interest Expense | $570.4M-8.0% | $620.0M+1.5% | $610.6M+57.7% | $387.3M+9.3% | $354.3M-11.7% | $401.1M+12.4% | $357.0M-21.3% | $453.7M+15.8% | $391.9M+19.8% | $327.1M-9.0% | $359.4M |
| Income Tax | $1.2B-1.8% | $1.2B+10.8% | $1.1B-44.9% | $2.0B+15.8% | $1.8B-20.2% | $2.2B+1526.8% | $135.8M-75.3% | $551.0M-73.4% | $2.1B+48.1% | $1.4B+81.6% | $769.9M |
| Net Income | $9.2B+59.3% | $5.8B-3.7% | $6.0B-33.3% | $9.0B+27.1% | $7.0B-53.2% | $15.0B+386.3% | $3.1B-37.3% | $4.9B-51.2% | $10.1B+103.6% | $5.0B+6.7% | $4.7B |
| EPS (Basic) | $7.51+63.4% | $4.60-3.6% | $4.77-33.4% | $7.16+27.2% | $5.63-53.2% | $12.01+377.6% | $2.51-36.4% | $3.95-50.9% | $8.05+108.6% | $3.86+8.4% | $3.56 |
| EPS (Diluted) | $7.48+63.0% | $4.59-3.6% | $4.76-33.2% | $7.12+27.2% | $5.60-53.1% | $11.95+377.3% | $2.50-36.3% | $3.93-50.8% | $7.98+108.4% | $3.83+8.5% | $3.53 |
| Diluted Shares (Avg) | 1.23B-2.4% | 1.26B0.0% | 1.26B0.0% | 1.26B0.0% | 1.26B-0.3% | 1.26B+0.2% | 1.26B+0.2% | 1.26B-0.9% | 1.27B-2.3% | 1.30B-1.9% | 1.32B |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.
SNY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $148.8B+8.3% | $137.5B-1.7% | $139.9B+3.2% | $135.6B-0.4% | $136.1B-2.7% | $139.9B+10.7% | $126.4B-0.9% | $127.6B+6.4% | $120.0B+8.6% | $110.5B-0.6% | $111.1B |
| Current Assets | $36.3B-17.6% | $44.1B+29.9% | $33.9B-7.0% | $36.5B+5.5% | $34.6B-16.1% | $41.2B+28.3% | $32.1B+14.1% | $28.2B-11.1% | $31.7B+12.5% | $28.2B+4.0% | $27.1B |
| Cash & Equivalents | $9.0B+16.7% | $7.7B-20.1% | $9.6B-29.3% | $13.6B+19.2% | $11.4B-32.8% | $17.0B+60.8% | $10.6B+33.4% | $7.9B-36.0% | $12.4B+14.4% | $10.8B+9.1% | $9.9B |
| Inventory | $12.0B+22.8% | $9.8B-8.7% | $10.7B+11.6% | $9.6B-2.8% | $9.9B-3.4% | $10.2B+13.8% | $9.0B+4.8% | $8.6B+4.5% | $8.2B+12.6% | $7.3B+2.8% | $7.1B |
| Goodwill | $48.5B+7.9% | $44.9B-17.8% | $54.7B+2.4% | $53.4B-1.9% | $54.4B+0.2% | $54.3B+8.6% | $50.0B-1.4% | $50.7B+4.7% | $48.4B+13.9% | $42.5B-1.0% | $43.0B |
| Total Liabilities | $65.1B+13.7% | $57.2B-1.3% | $58.0B+4.4% | $55.6B-4.8% | $58.4B-7.0% | $62.7B+4.3% | $60.1B-0.1% | $60.2B+19.9% | $50.2B+0.9% | $49.7B+3.4% | $48.1B |
| Current Liabilities | $33.3B+10.2% | $30.2B+12.7% | $26.8B+4.4% | $25.6B+6.4% | $24.1B+2.4% | $23.5B+2.9% | $22.9B+14.9% | $19.9B+7.1% | $18.6B+7.1% | $17.4B-5.0% | $18.3B |
| Non-Current Liabilities | $31.4B+17.7% | $26.7B-13.6% | $30.9B+4.6% | $29.5B-12.8% | $33.9B-13.2% | $39.0B+5.2% | $37.1B-7.6% | $40.1B+27.7% | $31.4B+1.5% | $30.9B+8.3% | $28.6B |
| Long-Term Debt | $16.9B+36.5% | $12.3B-23.0% | $16.0B-0.4% | $16.1B-16.7% | $19.3B-20.5% | $24.3B+8.1% | $22.5B-10.7% | $25.1B+47.4% | $17.1B-3.4% | $17.7B+25.5% | $14.1B |
| Total Equity | $83.8B+4.4% | $80.2B-2.0% | $81.9B+2.4% | $80.0B+2.9% | $77.7B+0.7% | $77.2B+16.4% | $66.3B-1.7% | $67.4B-3.4% | $69.8B+15.0% | $60.7B-3.7% | $63.0B |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Retained Earnings.
SNY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12.6B+34.2% | $9.4B-17.2% | $11.3B+0.8% | $11.3B-5.4% | $11.9B+31.3% | $9.1B+4.7% | $8.7B+36.3% | $6.4B-28.4% | $8.9B+7.3% | $8.3B-8.1% | $9.0B |
| Investing Cash Flow | -$2.9Bn/m | -$4.6Bn/m | -$6.9Bn/m | -$2.2Bn/m | -$8.3B-286.6% | $4.4Bn/m | -$1.3Bn/m | -$14.7Bn/m | -$3.5Bn/m | -$2.6Bn/m | -$3.3B |
| Financing Cash Flow | -$9.6Bn/m | -$6.0Bn/m | -$8.9Bn/m | -$6.2Bn/m | -$8.0Bn/m | -$7.9Bn/m | -$4.7B-204.5% | $4.5Bn/m | -$9.5Bn/m | -$4.3Bn/m | -$3.9B |
| Dividends Paid | $5.6B+15.0% | $4.9B-1.2% | $4.9B+10.5% | $4.5B-1.7% | $4.5B-5.8% | $4.8B+11.9% | $4.3B-0.4% | $4.3B-3.1% | $4.5B+12.4% | $4.0B-1.1% | $4.0B |
| Share Buybacks | $5.9B+1782.8% | $312.6M-52.3% | $656.0M+23.4% | $531.7M+23.0% | $432.3M-57.0% | $1.0B+7362.0% | $13.5M-98.9% | $1.3B-51.4% | $2.6B-15.3% | $3.1B+58.5% | $1.9B |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow.
SNY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.1%+1.9pp | 70.2%+0.5pp | 69.7%-1.0pp | 70.7%+2.0pp | 68.7%+1.3pp | 67.5%-0.7pp | 68.2%+0.2pp | 68.0%0.0pp | 67.9%-1.2pp | 69.2%+0.5pp | 68.7% |
| Operating Margin | 13.6%-2.8pp | 16.4%-0.3pp | 16.7%-8.3pp | 25.1%+4.3pp | 20.7%-17.0pp | 37.8%+29.7pp | 8.1%-5.0pp | 13.1%-2.9pp | 16.0%-2.8pp | 18.8%+2.7pp | 16.1% |
| Net Margin | 16.7%+4.2pp | 12.6%-0.4pp | 13.0%-7.7pp | 20.6%+4.7pp | 15.9%-17.0pp | 32.9%+25.6pp | 7.3%-4.8pp | 12.1%-11.2pp | 23.2%+9.7pp | 13.6%+1.3pp | 12.3% |
| Return on Equity | 10.9%+3.8pp | 7.2%-0.1pp | 7.3%-3.9pp | 11.2%+2.1pp | 9.1%-10.4pp | 19.5%+14.8pp | 4.7%-2.6pp | 7.3%-7.2pp | 14.5%+6.3pp | 8.2%+0.8pp | 7.4% |
| Return on Assets | 6.2%+2.0pp | 4.2%-0.1pp | 4.3%-2.3pp | 6.6%+1.4pp | 5.2%-5.6pp | 10.8%+8.3pp | 2.5%-1.4pp | 3.9%-4.6pp | 8.4%+3.9pp | 4.5%+0.3pp | 4.2% |
| Current Ratio | 1.09-0.4x | 1.46+0.2x | 1.27-0.2x | 1.420.0x | 1.44-0.3x | 1.75+0.3x | 1.400.0x | 1.41-0.3x | 1.70+0.1x | 1.62+0.1x | 1.48 |
| Debt-to-Equity | 0.200.0x | 0.150.0x | 0.200.0x | 0.200.0x | 0.25-0.1x | 0.310.0x | 0.340.0x | 0.37+0.1x | 0.240.0x | 0.29+0.1x | 0.22 |
| Liabilities-to-Equity | 0.78+0.1x | 0.710.0x | 0.710.0x | 0.69-0.1x | 0.75-0.1x | 0.81-0.1x | 0.910.0x | 0.89+0.2x | 0.72-0.1x | 0.82+0.1x | 0.76 |
| Asset Turnover | 0.370.0x | 0.330.0x | 0.330.0x | 0.320.0x | 0.330.0x | 0.330.0x | 0.330.0x | 0.320.0x | 0.360.0x | 0.330.0x | 0.34 |
Not reported in any period shown, so not listed: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Sanofi SNY | FY2025 | $54.8B | $9.2B | 16.7% | $100.5B | 60/100 |
| Pfizer Inc. PFE | FY2025 | $62.6B | $7.8B | 12.4% | $173.4B | 52/100 |
| Bristol-Myers Squibb Co. BMY | FY2025 | $48.2B | $7.1B | 14.6% | $128.7B | 51/100 |
| GSK plc GSK | FY2025 | $43.9B | $7.7B | 17.5% | $102.6B | 60/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $194.9B | 64/100 |
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $241.8B | 62/100 |
Where Sanofi Ranks
Frequently Asked Questions
What is Sanofi's annual revenue?
Sanofi (SNY) reported $54.8B in total revenue for fiscal year 2025. This represents a 19.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sanofi's revenue growing?
Sanofi (SNY) revenue grew by 19.6% year-over-year, from $45.8B to $54.8B in fiscal year 2025.
Is Sanofi profitable?
Yes, Sanofi (SNY) reported a net income of $9.2B in fiscal year 2025, with a net profit margin of 16.7%.
How much debt does Sanofi have?
As of fiscal year 2025, Sanofi (SNY) had $9.0B in cash and equivalents against $16.9B in long-term debt.
What is Sanofi's gross margin?
Sanofi (SNY) had a gross margin of 72.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sanofi's operating margin?
Sanofi (SNY) had an operating margin of 13.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sanofi's net profit margin?
Sanofi (SNY) had a net profit margin of 16.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sanofi's return on equity (ROE)?
Sanofi (SNY) has a return on equity of 10.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sanofi's operating cash flow?
Sanofi (SNY) generated $12.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Sanofi's total assets?
Sanofi (SNY) had $148.8B in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Sanofi spend on research and development?
Sanofi (SNY) invested $9.2B in research and development during fiscal year 2025.
What is Sanofi's current ratio?
Sanofi (SNY) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is Sanofi's debt-to-equity ratio?
Sanofi (SNY) had a debt-to-equity ratio of 0.20 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Sanofi's liabilities-to-equity ratio?
Sanofi (SNY) had a liabilities-to-equity ratio of 0.78 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Sanofi's return on assets (ROA)?
Sanofi (SNY) had a return on assets of 6.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sanofi's P/E ratio?
Sanofi (SNY) trades at 11.0x earnings, its market capitalization divided by $9.2B net income, FY2025. The market capitalization is $100.5B as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sanofi's price-to-sales ratio?
Sanofi (SNY) trades at 1.8x sales, its market capitalization divided by $54.8B revenue, FY2025. The market capitalization is $100.5B as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sanofi's Piotroski F-Score?
Sanofi (SNY) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sanofi's earnings high quality?
Sanofi (SNY) has an earnings quality ratio of 1.38x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sanofi cover its interest payments?
Sanofi (SNY) has an interest coverage ratio of 13.05x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sanofi?
Sanofi (SNY) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Sanofi it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.